Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

nium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

Post Your Comments:
(Date:11/26/2009)...ESBURG,SouthAfrica,Nov.26/PRNewswire/--The2009Fros...eGenericPharmaceuticalMarketispresentedtoCiplaMedp...com.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Forth...dtobenchmarkCiplaMedpro,sperformanceagainstkeycomp...novationinbusinessprocesses,productsand/ortechnolo...
(Date:11/25/2009)...D,Mass.,Nov.25/PRNewswire-FirstCall/--Hologic,Inc....oper,manufacturerandsupplierofpremiumdiagnostics,m...servingthehealthcareneedsofwomen,isusingtheannualm...atMcCormickPlaceinChicago,November29throughDecembe...dalitydiagnosticmammographyworkstationsoftware. ,...
(Date:11/25/2009)...Pa.,Nov.25/PRNewswire/--BioTrendsResearchGroup,Inc... report,thefirstinamulti-phasesyndicatedmarketrese...h,sStelara,fromproductlaunchthroughthefirstsixmont...tativeinformationfrom75uniqueDermatologistsandqual...trialanduseofStelara,obstaclestouse,typicalpatient...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Research reveals exactly how coughing is triggered by environmental irritants 10862 1Research reveals exactly how coughing is triggered by environmental irritants 10862 2Lose the fat 3A Targeting grease to curtail sewer overflows 10859 1Lose the fat 3A Targeting grease to curtail sewer overflows 10859 2Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 14943 1Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 14943 2
...irst Approved Systemic Therapy to Treat the Diseas...,Bayer HealthCare Pharmaceuticals and Onyx Pharmac... The New England Journal of Medicine published,res...(R) (sorafenib),tablets decreased the absolute ris...able hepatocellular carcinoma (HCC), or liver canc...
...23 Sound Pharmaceuticals (SPI) has filed,an Inves...he clinical,testing of a proprietary formulation o...ed hearing loss or ototoxicity. The oral capsule,c...anced stage lung cancer,and head and neck cancer p...s marks the second development program for SPI to ...
Other Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2
(Date:11/26/2009)..., NEWYORK,Nov.27/PRNewswire/--Withcoldandflus...racticestocontrolthespreadofinfectionsandavoidilln...veshealthy,buttoavoidtransmittingillnessifwe,resic...n-control),nursingdirectorforinfectioncontrolandoc...Manhattan. ,, HospitalforSpecialSurgeryhasoneof...
(Date:11/26/2009)... In the next 25 years, the number of Americans liv...rom 23.7 million in 2009 to 44.1 million in 2034. ...most triple, rising from $113 billion to $336 bill...esity, researchers based at the University of Chic... . , The number of those with diabetes covered b...
(Date:11/26/2009)...uggage that,s too big or too heavy can lead to str...lthDay News) -- There may be nothing wrong with st... not want to do the same thing with your suitcase ...00 people were treated in 2008 in U.S. hospital em... medical facilities for luggage-related injuries, ...
(Date:11/26/2009)... No more letters from the ...,personalized text messages from Santa , ...fort to increase operational efficiencies at the N... to help keep children all over the globe informed...Elves in Santa’s research department have id...
(Date:11/26/2009)... Research Triangle Dental ...tral North Carolina, today announced the expansion...ed LUMINEER Dentist, Dr. Doug Macmillan. , ...h Triangle Dental is pleased to announce that Dr. ..., recently completed an additional advanced traini...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
...(Nasdaq: MNKD ), focused on discovering, developi... cancer, announced today that it,will present at t...h 17,2008 at 3:15 PM ET at the Marriott Copley Pla...ny,s website at, http://www.mannkindcorp.com . A r...
...17 Citi Conference, CHICAGO, March 13 Brookdale ...hat management will make a presentation,regarding ...onference on,Wednesday, March 19, 2008 at 9:00 a.m...ons section of the Company,s website at, http://ww...
... traditional metal stents , , THURSDAY, Ma... quietly absorbed by the body after it has done it... well in an international trial, researchers repor...able stent had been implanted had closed again. On...
...care & Medicaid Services (CMS) today released a ne...ressure (CPAP) therapy for Medicare patients,with ...ciaries will be able,to undergo diagnosis for OSA ... American Academy,of Sleep Medicine (AASM), the le...
...millions of older adults, safety advocates and hea... $20.7 million for the,Centers for Disease Control...-scale problem of falls among older Americans., E... 1.8 million older adults were treated in emergenc...
...enosine linked to priapism , Priapism (prolonged...) is common in male individuals with sickle cell d...normally shaped red blood cells. Priapism is consi...ubsequently, erectile dysfunction and impotence. H...
Other Medicine News:Health News:Brookdale to Present at Lehman Global Healthcare Conference on March 19 2Health News:Melt-Away Stent Works Well in Trial 2Health News:Melt-Away Stent Works Well in Trial 3Health News:30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 2Health News:30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 3Health News:JCI online early table of contents: March 13, 2008 2Health News:JCI online early table of contents: March 13, 2008 3Health News:JCI online early table of contents: March 13, 2008 4Health News:JCI online early table of contents: March 13, 2008 5Health News:JCI online early table of contents: March 13, 2008 6Health News:JCI online early table of contents: March 13, 2008 7
Avant® 9700
Resolve® Immersion Oil
Immersion Oil, 150 cs
Immersion oil for microscopy
Medicine Products: